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25 
 SYNOPSIS 26 
Objectives: To develop a population model to describe the PK of intravenous meropenem in 27 
adult patients with severe burns and investigate potential relationships between dosage 28 
regimens and antimicrobial efficacy. 29 
Patients and methods: A dose of 1 g every 8 h was administered to adult patients with total 30 
ERG\VXUIDFHDUHDEXUQVRIDoses for subsequent courses were determined using results 31 
IURP WKH LQLWLDO FRXUVH DQG WKH SDWLHQW¶V FOLQLFDO FRQGLWLRQ )LYH SODVPD PHURSHQHP32 
concentrations were typically measured over the dosage interval on 1 ± 4 occasions.  An open 33 
two-compartment PK model was fitted to the meropenem concentrations using NONMEM and 34 
the effect of covariates on meropenem PK was investigated. Monte Carlo simulations 35 
investigated dosage regimens to achieve a target T>MIC for at least 40%, 60% or 80% of the 36 
dose interval. 37 
Results: Data comprised 113 meropenem concentration measurements from 20 dosage 38 
intervals in 12 patients. The parameters were CL (L/h) = 0.196 L/h/kg x (1-0.023 x (age - 46)) x 39 
(1- 0.049 x (albumin-15)), V1 = 0.273 L/kg x (1 - 0.049 x (albumin-15)), Q = 0.199 L/h/kg and V2 40 
= 0.309 L/kg x (1 ± 0.049 x (albumin-15)). For a target of 80% T>MIC, the breakpoint was 8 mg/L 41 
for doses of 1 g every 4 h and 2 g every 8 h given over 3 h but only 4 mg/L if given over 5 42 
minutes. 43 
Conclusions: Although 1 g eight-hourly should be effective against E. coli and coagulase 44 
negative Staphylococcus, higher doses, ideally with a longer infusion time, would be more 45 
appropriate for empiric therapy, mixed infections and bacteria with MIC values t 4 mg/L.  46 
47 
 INTRODUCTION  48 
Severely burned patients present several key challenges in their management, one being 49 
infection, which is a major cause of illness and death.1 The earliest organisms isolated from 50 
burn wounds tend to be Gram-positive organisms, such as Staphylococcus spp, but in the latter 51 
part of the first post-burn week, Gram-negative organisms become dominant, with 52 
Pseudomonas spp being the most common isolates.2,3 53 
Meropenem is a broad-spectrum E-lactam antibiotic commonly used to treat infections in 54 
patients with burn injuries. A survey of UK hospitals which treat severely burned adults found 55 
that thirteen of the sixteen respondents used meropenem as empiric therapy and / or if 56 
susceptible organisms were identified (unpublished data). In most units, the standard adult dose 57 
of 1g over 5 minutes every 8 h was used. However, it has been known since the 1970s that the 58 
pathophysiological changes which follow a major burn injury may affect the pharmacokinetics 59 
(PK) of drugs.4 These changes are influenced by a number of factors, including the presence of 60 
sepsis, the area and depth of the burn, serum protein concentration, age, CLCR, degree of 61 
hydration, presence of oedema and time after injury.5 As a result, several studies have 62 
recommended using higher antibiotic doses than are given to patients without burn injuries.6-9 63 
There is evidence to suggest that meropenem pharmacokinetics are also altered in severely 64 
burned patients5,10,11and within our own unit, we previously reported the case of a 27 year old 65 
man with a total body surface area (TBSA) burn of 52% in whom a dose increase to 1 g over 5 66 
minutes every 4 h was needed to achieve target serum concentrations.12 No previous 67 
population studies have examined intraindividual variability in pharmacokinetic parameters in 68 
this patient group. 69 
Since meropenem demonstrates time-dependent killing at clinically relevant 70 
concentrations,13the most important pharmacodynamic (PD) index to predict antimicrobial 71 
 efficacy is the percentage of the dosing interval that the antibiotic concentrations remain above 72 
the MIC of the pathogenic organism (T>MIC). Many PD studies have selected a T>MIC for at least 73 
40% of the dose interval as the target.14-19 However, as treatment with meropenem is often 74 
empiric, the MIC is not known. Whilst the EUCAST 201320 susceptibility breakpoint of 2 mg/L 75 
could be selected as the target MIC, a 2009 study of meropenem activity against nosocomial 76 
isolates across Europe found 79% of Pseudomonas aeruginosa isolates susceptible at a 77 
breakpoint of 4 mg/L21 suggesting this might be a more suitable target. However, such 78 
considerations should always be based on local epidemiology, where it is available.  In this 79 
context, dosage regimens can be optimised through integration of PK-PD targets, derived from 80 
both PK data and exposure-response data, with Monte Carlo simulation to predict the probability 81 
of attaining a specific PD target at various dosage regimens.15,22 82 
The aim of this study was to determine the PK profile of intravenous meropenem given at an 83 
initial dose of 1g over 5 minutes every 8 h to adult patients admitted to hospital with severe 84 
burns, to develop a population model to describe the PK of meropenem in this patient group, 85 
and to use Monte Carlo simulation techniques to investigate potential relationships between 86 
dosage regimens and the achievement of PK/PD targets. 87 
88 
 PATIENTS AND METHODS 89 
Patients  90 
Adults admitted to a Regional Burns Centre with a major burn (defined as a TBSA burn of at 91 
least 15%), receiving meropenem, were eligible for inclusion in the study.  Consent was 92 
obtained from patients who were deemed fit to give it.  For incapacitated adults, assent was 93 
obtained from the next of kin, and consent to use the data sought retrospectively from those 94 
patients who survived their injury. The study was approved by the Trust Research and 95 
Development Committee, the National Ethics Research Committee 3/3/045 and the MHRA 96 
(Reference 21310/0001/001-002).  97 
Patient demographics (gender, age, weight and height), burn details (TBSA burn, full and partial 98 
thickness burn surface area and percentage burn remaining at time of diagnosis of infection), 99 
routine clinical data (e.g. serum creatinine and serum albumin) and antibiotic prescribing 100 
information were collected for each patient. In addition, the following data were recorded: post-101 
burn day when blood samples were taken; length of stay in the Intensive Therapy Unit (ITU); 102 
Abbreviated Burn Severity Index (ABSI) Score23 and patient outcome. 103 
Study protocol 104 
Initial courses of meropenem commenced at a standard dose of 1 g over 5 minutes every 8 h, 105 
as per Trust antimicrobial guidelines. After at least 24 h of therapy, blood samples were taken at 106 
the following times: predose; 30 minutes, 1, 2 and 4 h post dose; and immediately before the 107 
next dose. Blood samples (3 mL) were collected using serum gel tubes, centrifuged at 4,500 108 
rpm, then the resulting serum was separated into plain 2 mL plastic tubes, stored and 109 
transported at 40C for analysis within 24 hours, in line with previous published stability data.24 110 
Samples were analysed by HPLC at the National Antimicrobial Reference Laboratory (approved 111 
 by Clinical Pathology Accreditation Ltd (UK)) using a previously reported method.25 This has a 112 
lower limit of detection of 0.3 mg/L and a limit of quantification of 1 mg/L, where the intra and 113 
inter assay coefficient of variation (CV)% were both less than 10%. The results were reported 114 
within 24 hours and the dosage regimen was then modified if necessary and when the length of 115 
course allowed to maintain concentrations above 4 mg/L for at least 40% of the dose interval. If 116 
a patient required a second or third course of meropenem, the decision of what starting dose to 117 
XVHZDVLQIOXHQFHGE\UHVXOWVIURPWKHLQLWLDOFRXUVHDQGWKHSDWLHQW¶VFOLQLFDOFRQGLWLRQ6HUXP118 
concentrations were measured and doses amended as described for initial courses. 119 
Pharmacokinetic analysis 120 
A population PK modelling approach was applied to the data using NONMEM Version 7.2.26 121 
(ICON Development Solutions, Ellicott City, MD, USA) with first order conditional estimation and 122 
interaction (FOCEI). Post-processing of the NONMEM results was performed with R 2.1.4.027 123 
and diagnostic plots were performed with Xpose version 4 programmed in R 2.1.4.0.28 124 
Based on a graphical exploratory analysis, an open, two-compartment model with zero order 125 
input and linear elimination and linear distribution from the central to peripheral compartment 126 
was selected to describe the meropenem plasma concentrations after intravenous 127 
administration. This model was parameterized in terms of CL, central volume of distribution (V1), 128 
intercompartmental clearance (Q) and volume of distribution of the peripheral compartment (V2). 129 
Observed Cmax was defined as the measured serum concentration at 30 minutes in each 130 
patient. Individual parameter estimates were obtained from the Empirical Bayes Estimates 131 
(EBEs) and were used to calculate half-lives; AUC0-24was calculated from the total daily dose 132 
and individual estimates of CL. 133 
Log-normal distributions were assumed for between-subject variability (BSV) and between 134 
RFFDVLRQ YDULDELOLW\ %29 LQ WKH 3. SDUDPHWHUV DQ ³RFFDVLRQ´ ZDV GHILQHG DV D VHW RI135 
 concentration-time data collected over one day. A proportional model was used to describe the 136 
residual error. The shrinkage of the EBE of the BSV were calculated as previously suggested.29 137 
Once the base model had been identified and, in the absence of significant shrinkage, EBE of 138 
the BSV were used to identify potential relationships between individual PK estimates and the 139 
clinical covariates gender, age, weight (using linear and allometric relationships), serum 140 
creatinine concentration, measured CLCR, serum albumin, percentage of TBSA burn, 141 
percentage of full and partial thickness burn surface area, percentage burn remaining at time of 142 
diagnosis of infection and post-burn day. These covariates were first examined using scatter 143 
plots then added to and removed from the population model in a stepwise manner.30 144 
Improvements in the fit obtained with each model were assessed in several ways. First, the 145 
NONMEM generated objective function value (OFV) was used to perform the likelihood ratio 146 
WHVW$GHFUHDVHLQ2)9RIZDVUHTXLUHGWRUHDFKVWDWLVWLFDOVLJQLILFDQFHS IRU147 
the addition of one fixed effect in a hierarchical model. In addition, improvement in the fit was 148 
assessed by reductions in the BSV, BOV, residual variability and standard errors of the 149 
parameter estimates.  Diagnostic plots and shrinkage were also examined.29 150 
The final population model was evaluated in three ways: a non-parametric bootstrap sampling 151 
procedure with 1,000 samples was conducted using PsN toolkit31 and a prediction-corrected 152 
visual predictive check (pcVPC) was based on 1,000 simulations.32 Finally, normalised 153 
prediction distribution errors (NPDE) obtained from 10,000 simulations were computed using the 154 
software developed by Brendel et al.33 155 
Pharmacodynamic simulations 156 
The final PK model was used for simulations that were undertaken to explore the role of the 157 
dosage regimen on the probability of target attainment (PTA). The final parameters of the 158 
 population PK model were used to generate individual total drug concentration profiles for each 159 
of the 1,000 simulated patients using NONMEM. The clinical characteristics of the simulated 160 
patients mirrored those of the original patient group. Simulations were performed for four steady 161 
state dosage regimens given by bolus injection over 5 minutes: 1 g every 8 h; 2 g every 8 h; 1 g 162 
every 6 h; 1 g every 4 h. In addition, three 3 hour infusion regimens: 1 g every 8 h; 2 g every 8 h 163 
and 1 g every 6 h and steady state concentrations arising from three continuous infusions: 3, 4 164 
and 6 g over 24 h were simulated. For evaluation of these dosage regimens, MIC values were 165 
chosen across the range 0.125-128 mg/L. In each patient, the time that the drug concentration 166 
remained above the MIC was calculated as the cumulative percentage of the dosage period.34 167 
For each MIC and dosing regimen, PTA was defined as the probability of 1000 simulated 168 
patients achieving the target T>MIC for at least 40%, 60% or 80% of the dose interval. For each 169 
meropenem regimen, the highest MIC at which the PTA was ZDVGHILQHGDVWKH3.-PD 170 
susceptible breakpoint.  171 
A second analysis was conducted using MIC distributions of Escherichia coli, coagulase 172 
negative Staphylococcus, P. aeruginosa and Enterococcus faecalis derived from the EUCAST 173 
database.20 These MIC distributions were extracted from 8005 strains of E. coli, 143 strains of 174 
coagulase negative Staphylococcus, 57505 strains of P. aeruginosa and 12369 strains of E. 175 
faecalis. The cumulative fraction of response (CFR) was used to estimate the overall response 176 
of pathogens to meropenem for each of the ten dosage regimens, subdivided according to CL. 177 
This estimate accounts for the variability of drug exposure in the population and the variability in 178 
the MIC combined with the distributions of MICs for the pathogens. For each MIC, the fraction of 179 
simulated patients who met the PD target was multiplied by the fraction of the distribution of 180 
microorganisms for each MIC. The CFR was calculated as the sum of fraction products over all 181 
MICs. 182 
 183 
 RESULTS 184 
Patient Demographics 185 
Twelve patients (7 male) were recruited to the study with a mean age at the time of the first 186 
course of 46 years (range 27 to 73).The median percentage of TBSA burn was 41% (range 20 187 
to 80) and the median ABSI Score was 10 (range 5 to 12). Most burns (n = 10) resulted from 188 
flame injuries; inhalation injury was present in 7 cases. All patients were mechanically 189 
ventilated, spending a median of 40.5 days in intensive care (range 19 to 119 days). Five did 190 
not survive their injury. The following pathogenic bacteria were isolated: coagulase negative 191 
Staphylococcus in 9 patients; P. aeruginosa in 4 patients, mixed coliforms and Enterococcus 192 
spp in 4 patients, E. coli, Stenotrophomonas maltophilia and Enterobacter cloacae in 3 patients. 193 
Other microorganisms found were E. faecalis, Bacillus cereus, Staphylococcus aureus, 194 
Acinetobacter baumannii, Haemophilus influenzae, Klebsiella spp and Proteus mirabilis. 195 
In general, renal function was not impaired at the time of recruitment into the study and none of 196 
the patients required renal replacement therapy. The median (range) of serum creatinine was 197 
41 Pmol/L (22 to 112) and of measured CLCR was 136.5 ml/min (60 to 217).  Measured CLCR 198 
was only available for 8 of the 12 patients. 199 
Serum Concentration-Time Profiles 200 
A total of 113 plasma meropenem concentration measurements were available, with a median 201 
of 9 (range 4-24) measurements per patient. One high trough concentration that was 202 
inconsistent with all other data from the same patient was removed from the analysis. Overall, 203 
there were 20 sets of measurements (occasions); 7 patients had one occasion, 3 patients had 204 
two occasions, 1 patient had three occasions and 1 patient had four occasions. Individual 205 
concentration-time profiles are presented in Figure 1. 206 
 Patients initially received a standard intravenous infusion of meropenem over 5 minutes at 207 
doses of 1 g every 8 h for 3-5 consecutive days. In seven patients, sub-optimal serum 208 
concentrations were reported, which required an increase in the frequency of administration in 209 
three patients to 1 g every 6 h, in one patient to 2 g every 8 h and to 1 g every 4 h in one 210 
patient. Observed Cmax ranged from 9.2 to 79.2 mg/L with a mean (SD) of 28.4 (16.1) mg/L 211 
while the pre-dose trough ranged from 0.3 to 19.2 mg/L with a mean (SD) of 2.8 ±4.2 mg/L. 212 
Pharmacokinetic Analysis 213 
An open two compartment disposition model with zero order input and linear elimination and 214 
distribution adequately described the time course of plasma concentration following meropenem 215 
administration.  216 
All parameters were linearly related to body weight. Scatterplots of individual estimates of the 217 
parameters against the measured and derived clinical and demographic data identified 218 
additional potential relationships between CL and age, measured CLCR, serum albumin, TBSA 219 
burn, full thickness burn surface area and percentage burn remaining at time of diagnosis of 220 
infection. Relationships were identified between V1 and V2 and serum albumin; only the inclusion 221 
of age on CL and serum albumin on CL, V1 and V2 achieved statistically significant reductions in 222 
the OFV when included individually in the population model. A further improvement in the fit was 223 
achieved by including BOV in CL in the model. The final population model reduced the OFV 224 
from 385.5 (base model) to 276.0 and had the following structure: 225 
CL = 0.196 L/h/kg x (1-0.023 x (age - 46)) x (1- 0.049 x (albumin-15)) 226 
V1 = 0.273 L/kg x (1 - 0.049 x (albumin-15)) 227 
Q = 0.199 L/h/kg  228 
 V2 = 0.309 L/kg x (1 ± 0.049 x (albumin-15)) 229 
The population model identified a typical whole body clearance estimate of 0.196 L/h/kg in a 230 
patient with the mean age of 46 years and the mean albumin concentration of 15 g/L. Inclusion 231 
of weight, age and albumin reduced BSV in CL and Q from 47.2% and 94.4%, respectively, to 232 
negligible values. The shrinkage of BSV in V2 was estimated at 27.6%. BOV for V1, V2 and Q 233 
were negligible and fixed to 0; BOV for CL was 28.8%. The population model predicted a wide 234 
range of CL estimates (0.082 to 0.352 L/h/kg), which mainly reflected the age range of the 235 
patients. Individual parameter estimates for each patient on each occasion are listed in Table 1. 236 
The mean CL was 18.4 L/h and ranged from 5.3 to 36.0 L/h; mean estimates of distribution and 237 
elimination half-lives were 0.4 h (range 0.3 to 0.6 h) and 2.9 h (range 1.3 to 9.7 h), respectively. 238 
AUC0-24 ranged from 83 to 563 mg·h/L (mean 226 mg·h/L).  239 
The final population model parameters and non-parametric bootstrap estimates are presented in 240 
Table 2. From 1,000 replicates analysed during the bootstrap analysis, 11% failed to minimize 241 
successfully and were excluded. The population estimates of the final model were similar to the 242 
mean of the non-parametric bootstrap replicates that minimized successfully and were 243 
contained within the 95% confidence intervals. The precision of the NONMEM parameter 244 
estimates was also acceptable except for BSV in V2, which had a standard error >80% and had 245 
to be fixed to the estimated value. Likewise, histograms of distributions of the individual random 246 
effects on parameters were centred around the population typical value (data not shown) and 247 
the pcVPC presented in Figure 2 demonstrates consistency between the model predictions and 248 
the raw data. Finally, the NPDE check confirmed a normal distribution around each individual 249 
observation within the predictions of the model. 250 
Pharmacodynamic analysis 251 
 The percentages of simulated patients who achieved 40%, 60% or 80% of T>MIC at each MIC 252 
value with six of the meropenem dosage regimens are presented in Figure 3. For targets of 40% 253 
and 60% T>MIC, the PK-PD breakpoint was 8 mg/L for a dose of 1 g every 8 h if given over 3 h 254 
but only 4 mg/L if administered over 5 minutes. For a target of 80% T>MIC the PK-PD breakpoint 255 
was 8 mg/L for all infusions and doses of 1 g 4 hourly and 2 g over 3 h every 8 h but reduced to 256 
4 mg/L if the 8 hourly dose was given over 5 minutes. Table 3 shows that when the results were 257 
integrated with the MIC distribution for each organism and split according to CL estimates, the 258 
cumulative fraction of response (CFR) for the all targets were % with all the dosage 259 
regimens for E. coli and coagulase negative Staphylococcus. For E. faecalis and P. aeruginosa, 260 
the CFRs were >89% for all the continuous infusions, except for doses of 3 and 4 g daily in  261 
patients whose CL was > 20 L/h. Continuous infusions consistently achieved better results than 262 
3 hour infusions and 3 hour infusions were better than bolus administration. The lowest CFR 263 
results were obtained with a dose of 1 g every 8 h over 5 minutes, which was only acceptable 264 
for patients whose CL estimates were < 10 L/h. 265 
DISCUSSION 266 
This study determined the population PK of meropenem following intravenous doses of 1-2 g 267 
given every 4-8 h to a group of twelve adults with severe burns. The influence of patient 268 
covariates on PK parameters and PK-PD relationships were investigated with the aim of 269 
proposing a suitable dose regimen for this population.  270 
The 2-compartment structural model was in line with other studies of meropenem PK.10,19 Whilst 271 
considerable inter-patient variability was observed in the meropenem PK values, the mean 272 
clearance and volume of distribution estimates were around 20-40% higher than those reported 273 
in other patient groups.19,25,35,36 Physiological changes and excessive hydration in patients with 274 
major burns can adversely affect the PK of antibiotics and increase both CL and volume of 275 
 distribution.  Even greater increases in V would be expected in patients with large burns due the 276 
increased extracellular fluid volume and hydration required to compensate for the loss of 277 
intravascular fluid accompanying hypoalbuminaemia.4 278 
A recent study of Korean patients with burn injuries10 explored the relationship between 279 
meropenem dose and the likelihood of achieving serum concentrations above the MIC of P. 280 
aeruginosa for >40% of the dosing interval. Although they reported higher clearance and 281 
distribution volumes than seen in non-burn patients, their estimates were lower than observed in 282 
our study. These findings may reflect differences in the characteristics of the patients since 283 
serum albumin concentrations were markedly lower (15 compared with 27 g/L) and body weight 284 
higher (83 compared with 66 kg) in our study. 285 
The final population model related all parameters linearly to body weight, which is consistent 286 
with the findings of early population PK analyses.16,35 The identification of age and serum 287 
albumin as factors influencing the PK of meropenem, with age having the greater effect, also 288 
correspond well with previous findings.18,35 Meropenem is primarily renally cleared36 and the 289 
effect of age probably reflects an age-related change in renal function. Although renal function 290 
has been included as a covariate in other population studies,5,19 it could not be properly 291 
investigated in this study. The small number of patients and lack of renal impairment were 292 
contributing factors but an additional issue was that due to technical difficulties in collecting 293 
urine, measured CLCR values were only available for 14 of the 20 occasions in 8 of the 12 294 
patients. Using an equation to estimate CLCR, such as the Cockcroft-Gault equation,
37 was 295 
unsatisfactory because there was a very poor correlation between estimated and measured 296 
CLCR values. Similar findings were previously reported by Conil et al,
38 who concluded that 297 
formulae based on serum creatinine are imprecise in assessing renal function in burn patients 298 
and should be abandoned in favour of direct measurement based on a 24 h urine collection. 299 
Serum albumin was found to influence CL, V1 and V2. Hypoalbuminaemia is a consequence of 300 
 the hypermetabolic phase because of leakage to the extravascular fluid and decreased hepatic 301 
production4 and is consistent with higher estimates of these parameters.  302 
Although a weak correlation between meropenem CL and TBSA burn was identified with the 303 
base model, in contrast with the findings of Doh et al,10 attempts to estimate the effect of TBSA 304 
on the parameters failed, probably because there were insufficient data to support a relationship 305 
in the population model due to the relatively small number of patients.  306 
This study identified an influence of weight, age and albumin concentration on the 307 
pharmacokinetics of meropenem.  However, with such a small data set, there is limited power to 308 
conduct a comprehensive covariate analysis and the clinical impact of these covariates cannot 309 
be clearly defined.  When these factors were included in the model, between subject variability 310 
in CL could no longer be identified.  This might be interpreted as indicating that all variability 311 
between individuals was explained by these covariates.   However, between occasion variability 312 
remained high and a more likely explanation is that meropenem pharmacokinetics change so 313 
much within a patient who has a burn injury that it cannot be separated from pharmacokinetic 314 
variability between patients. The results presented in Table 1 for patient 6 support this 315 
suggestion.  Clearance estimates ranged from 14 to 36 L/h despite minimal changes in age, 316 
weight or albumin concentration between occasions. 317 
Based on the developed model, the Monte Carlo simulations determined the PK-PD breakpoints 318 
for a range of meropenem regimens and MIC values. It was noticeable that of the five patients 319 
who did not survive their injury, three had serum concentrations above 4 mg/L for more than 320 
40% of the dose interval at their starting dose of 1 g every 8 h. Although these poor outcomes 321 
may have reflected other aspects RIWKHSDWLHQW¶VFRQGLWLRQLWPD\DOVRVXJJHVWWKDWDWDUJHWRI322 
40% of the dose interval above 4 mg/L was insufficient. In their study of meropenem in febrile 323 
neutropenic patients, Ariano et al calculated the mean T>MIC to be 83% for clinical responders 324 
 compared with 59% for non responders39.  This is in line with another clinical study of beta-325 
lactams which showed a significantly greater outcome when T>MIC was at least 80%. 
40  In the 326 
present study, a regimen of 1 g over 5 minutes every 8 h would be sufficient to achieve 80% 327 
T>MIC against highly susceptible bacteria, such E. coli and coagulase negative Staphylococcus. 328 
However, for infections due to E. faecalis or less susceptible strains of P. aeruginosa, a dose of 329 
1 g over 5 minutes every 4 h may be necessary to achieve 80% T>MIC. Given the low toxicity risk 330 
of high dose meropenem41 in patients without renal impairment, and the possible consequences 331 
of sub-therapeutic dosing, a dose of 1g every 4 h should be considered in patients with 332 
infections caused by these organisms and also for empiric treatment. A better approach may be 333 
to administer meropenem by infusion, either over 3 hours42 or by continuous infusion.43 334 
However, although a continuous infusion would improve the T>MIC, there may be practical 335 
limitations due stability issues with meropenem.44 Additionally, with continuous infusion there is 336 
always the risk of T>MIC of 0%, if a patient has an unusually high meropenem clearance. For 337 
infections caused by a known organism with a known MIC, the regimen could be tailored 338 
according to the pharmacokinetic data presented in this study. 339 
 340 
In summary, the PK of intravenous meropenem in adults with severe burns is influenced by age, 341 
body weight and serum albumin but there is wide between and within patient variability in CL 342 
and V2. Although a dose of 1 g eight-hourly should be effective against E. coli and coagulase 343 
negative Staphylococcus, a higher dose of 1 g over 5 minutes every 4 h or 2 g over 3 h every 8 344 
h would be more appropriate for empiric therapy, mixed infections and bacteria with MIC values 345 
of 4 mg/L and above. 346 
 ACKNOWLEDGEMENTS 347 
We gratefully acknowledge to input from pharmacy, nursing, medical and library staff at the 348 
Queen Victoria Hospital NHS Foundation Trust. Additionally our thanks go to the Regional 349 
Antimicrobial Laboratory at Southmead Hospital for the processing of the assays and the advice 350 
provided. 351 
FUNDING 352 
This work was supported by the Galen Award 2008 awarded by the Royal Pharmaceutical 353 
Society. The cost of meropenem assays were met by Astra Zeneca.  Unconditional educational 354 
grants were received from Pfizer and Forest Laboratories to purchase equipment and to support 355 
courier costs. 356 
TRANSPARENCY DECLARATIONS 357 
All authors: None to declare. All support from the pharmaceutical industry was unconditional. 358 
The authors did not seek advice concerning any aspect of the design, analysis or interpretation 359 
of the data from any industrial sponsor. The manuscript has not been viewed, revised or edited 360 
by any employee of the companies listed above. 361 
REFERENCES 362 
1. Pruitt BA, Jr. The diagnosis and treatment of infection in the burn patient. Burns Incl 363 
Therm Inj 1984; 11: 79-91. 364 
2. Revathi G, Puri J, Jain BK. Bacteriology of burns. Burns 1998; 24: 347-9. 365 
3. Donati L, Scamazzo F, Gervasoni M et al. Infection and antibiotic therapy in 4000 burned 366 
patients treated in Milan, Italy, between 1976 and 1988. Burns 1993; 19: 345-8. 367 
 4. Blanchet B, Jullien V, Vinsonneau C et al. Influence of burns on pharmacokinetics and 368 
pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 369 
47: 635-54. 370 
5. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. Journal of Antimicrobial 371 
Chemotherapy 1999; 44: 319-27. 372 
6. Zaske DE, Sawchuk RJ, Gerding DN et al. Increased dosage requirements of 373 
gentamicin in burns patients. JTrauma1976; 16: 824 - 8. 374 
7. Garrelts JC, Peterie JD. Altered vancomycin dose vs. serum concentration relationship 375 
in burn patients. Clin Pharmacol Ther 1988; 44: 9-13. 376 
8. Garrelts JC, Jost G, Kowalsky SF et al. Ciprofloxacin pharmacokinetics in burn patients. 377 
Antimicrob Agents Chemother 1996; 40: 1153-6. 378 
9. Bourget P, Lesne-Hulin A, Le Reveille R et al. Clinical pharmacokinetics of piperacillin-379 
tazobactam combination in patients with major burns and signs of infection. Antimicrob 380 
Agents Chemother 1996; 40: 139-45. 381 
10.  Doh K, Woo H, Hur J et al. Population pharmacokinetics of meropenem in burn patients. 382 
Journal of Antimicrobial Chemotherapy 2010; 65: 2428-35. 383 
11. Lin C, Liu SQ, Dai Q et al. Pharmacokinetics of meropenem in the patients with burn 384 
injury. Chinese Journal of Antibiotics 2004; 29: 118-23. 385 
12.  Hallam MJ, Allen JM, James SE et al. Potential subtherapeutic linezolid and meropenem 386 
antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care 387 
Res2010; 31: 207-9. 388 
13. Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. 389 
Clinical Infectious Diseases 2003; 36: S42-S50 390 
14. Bui KQ, Ambrose PG, Nicolau DP et al. Pharmacokinetics of high-dose meropenem in 391 
adult cystic fibrosis patients. Chemotherapy 2001; 47: 153-6. 392 
 15. Krueger WA, Bulitta J, Kinzig-Schippers M et al. Evaluation by Monte Carlo simulation of 393 
the pharmacokinetics of two doses of meropenem administered intermittently or as a 394 
continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 1881-395 
9. 396 
16. Lee DG, Choi SM, Shin WS et al. Population pharmacokinetics of meropenem in febrile 397 
neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28: 333-9. 398 
17. Santos Filho L, Eagye KJ, Kuti JL et al. Addressing resistance evolution in 399 
Pseudomonas aeruginosa using pharmacodynamic modelling: Application to 400 
meropenem dosage and combination therapy. Clin Microbiol Infect 2007; 13: 579-85. 401 
18. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. Meropenem dosing in critically ill patients 402 
with sepsis and without renal dysfunction: intermittent bolus versus continuous 403 
administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J 404 
Antimicrob Chemother 2009; 64: 142-50. 405 
19. Ikawa K, Morikawa N, Ohge H et al. Pharmacokinetic-pharmacodynamic target 406 
attainment analysis of meropenem in Japanese adult patients. J Infect Chemother2010; 407 
16: 25-32. 408 
20. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. 409 
www.eucast.org (21May 2014, date last accessed). 410 
21. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum 411 
agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63: 217-22. 412 
22. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an 413 
optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 414 
2003;43:1116-1123. 415 
23. Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann Emerg 416 
Med 1982; 11: 260-2. 417 
 24. Elkhaili H, Niedergang S, Pompei D et al. High-performance liquid chromatographic 418 
assay for meropenem in serum. J Chromatogr B Biomed Appl 1996; 686: 19-26. 419 
25. Lovering AM, Vickery CJ, Watkin DS et al. The pharmacokinetics of meropenem in 420 
surgical patients with moderate or severe infections. J Antimicrob Chemother 1995; 36: 421 
165-72. 422 
26. Beal S, Sheiner LB, Boeckmann A et al. NONMEM User's Guides. (1989-2009), Icon 423 
Development Solutions, Ellicott City, MD, USA,2009. 424 
27.   Venables WN, Smith DM, R Development Core Team. R version 2.1.4.0. The R 425 
Foundation for Statistical Computing. http://cranr-project.org  426 
28. Jonhsson EN, Karlsson MO. Xpose-an S-PLUS based population 427 
pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods 428 
Programs Biomed 1999;58:51-64. 429 
29. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 430 
2007;82:17±20. 431 
30. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building 432 
strategies in populationpharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 433 
2002;4:E27 434 
31. Lindbom L, Pihlgren P, Jonsson EN.PsN-Toolkit - a collection of computer intensive 435 
statistical methods for non-linear mixed effect modeling using NONMEM.Comput 436 
Methods Programs Biomed. 2005;79:241-57. 437 
32. Bergstrand M, Hooker AC, Wallin JE et al. Prediction-Corrected Visual Predictive 438 
Checks for Diagnosing Nonlinear Mixed-Effects Models. AAPS J2011; 13: 143±151.33. 439 
33.  Brendel K, Comets E, Laffont C et al. Metrics for externalmodelevaluation with an 440 
application to the population pharmacokinetics of gliclazide.Pharm Res 2006;23:2036-441 
49. 442 
 34. Mouton JW, Dudley MN, Cars Oet al. Standardization of 443 
pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an 444 
update. J Antimicrob Chemother 2005;55:601-7. 445 
35. Li C, Kuti JL, Nightingale CH et al. Population pharmacokinetic analysis and dosing 446 
regimen optimization of meropenem in adult patients. J Clin Pharmacol2006;46:1171-8. 447 
36. Christensson BA, Nilsson-Ehle I, Hutchison M et al. Pharmacokinetics of meropenem in 448 
subjects with various degrees of renal impairment. Antimicrob Agents Chemother 449 
1992;36:1532-1537. 450 
37. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. 451 
Nephron 1976; 16: 1-41 452 
38. Conil JM, Georges B, Fourcade O et al. Assessment of renal function in clinicalpractice 453 
at the bedside ofburn patients. Br JClin Pharmacol 2007; 63: 583-94. 454 
39. Ariano RE, Nyhlen A, Donnelly, JPet al. Pharmacokinetics and pharmacodynamics of 455 
meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005;39: 456 
32-38. 457 
40. McKinnon PS, Paladino JA, and Schentag JJ. Evaluation of area under the inhibitory 458 
curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as 459 
predictors of outcome for cefepime and ceftazidime in serious bacterial infections. 460 
International Journal of Antimicrobial Agents31: 345-351 461 
41. Bulik CC, Quintiliani R, Samuel J et al. Pharmacodynamics and tolerability of high-dose, 462 
prolonged infusion carbapenems in adults with cystic fibrosis - A review of 3 cases. 463 
Respiratory Medicine CME 2010; 3: 146-9. 464 
42. Bulik CC, Christensen H, Peng Li P et al. Comparison of the activity of a human 465 
simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae 466 
producing the KPC carbapenemase versus that against Pseudomonas aeruginosa 467 
in an In Vitro pharmacodynamic model. Antimicrob Agent Chemother 2010;54: 804-810. 468 
 43. Roberts JA, Kirkpatrick CA, MS et al. Roberts Meropenem dosing in critically ill patients 469 
with sepsis and without renal dysfunction: intermittent bolus versus continuous 470 
administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J 471 
Antimicrob Chemother 2009; 64: 142-150. 472 
44. Berthoin K, Le Duff CS, Marchand-Brynaert J et al. Stability of meropenem and 473 
doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 474 
2010; 65:  1073 ± 1075. 475 
 Table 1 Individual estimates of PK parameters on each sampling occasion 476 
Patient 
number 
Occ 
Daily dose 
(mg) 
Age 
(years) 
Weight 
(kg) 
Albumin  
(g/L) 
AUC0-24 
(mg.h/L) 
CL 
(L/h) 
V1 
(L) 
V2 
(L) 
Q  
(L/h) 
Dt1/2 
(h) 
Et1/2 
(h) 
1 1 3000 27 68 15 146 20.5 18.6 20.4 13.5 0.32 2.0 
2 1 3000 38 53 13 164 18.2 15.9 12.2 10.5 0.31 1.6 
2 2 6000 38 65 10 443 13.5 22.1 17.0 12.9 0.41 2.5 
2 3 4000 38 65 9 231 17.4 23.0 17.6 12.9 0.40 2.2 
3 1 3000 62 114 15 208 14.4 31.1 29.8 22.6 0.40 3.4 
4 1 3000 73 87 13 336 8.9 26.1 30.7 17.3 0.48 5.2 
5 1 3000 45 93 12 111 26.9 29.1 37.2 18.5 0.39 2.7 
6 1 3000 35 102 15 83 36.0 27.8 39.3 20.3 0.31 2.3 
6 2 3000 35 100 15 99 30.3 27.3 38.6 19.9 0.33 2.5 
6 3 4000 35 100 17 203 19.7 24.6 34.8 19.9 0.36 2.9 
6 4 4000 35 100 16 285 14.0 25.9 36.7 19.9 0.41 4.0 
7 1 3000 37 65 24 229 13.1 9.9 9.4 12.9 0.20 1.3 
8 1 3000 27 74 15 118 25.3 20.2 20.5 14.7 0.30 1.8 
8 2 6000 27 74 15 238 25.2 20.2 20.5 14.7 0.30 1.8 
9 1 3000 40 65 14 176 17.1 18.6 16.1 12.9 0.34 1.9 
9 2 4000 40 75 18 297 13.5 17.4 15.1 14.9 0.30 2.1 
10 1 3000 59 99 16 220 13.6 25.7 25.1 19.7 0.37 3.1 
10 2 3000 59 70 15 221 13.6 19.1 18.7 13.9 0.36 2.5 
11 1 3000 70 86 10 563 5.3 29.2 38.0 17.1 0.61 9.7 
12 1 3000 39 103 18 141 21.3 23.9 23.0 20.4 0.30 2.0 
Mean  3500 46 82.9 14.8 226 18.4 22.8 25.0 16.5 0.4 2.9 
SD  950 16 17.5 3.3 118 7.4 5.3 9.8 3.5 0.1 1.8 
 477 
 Abbreviations Occ, sampling occasions; CL, clearance; V1, volume of the central compartment; V2, volume of the peripheral compartment; Q, 478 
intercompartmental clearance; AUC0-24, daily area under the concentration-time curve;Dt1/2, distribution half-life; Et1/2, elimination half-life 479 
  480 
 Table 2 Parameter estimates and bootstrap analysis of the final population PK model for meropenem in patients with burn injuries 481 
 482 
Pharmacokinetic Parameter Central Tendency (SE) 
Non-Parametric Bootstrap 
Mean (SE) 95% Confidence Interval 
CL(L/h/kg) 0.196 (0.013) 0.201 (0.016) 0.169 - 0.223 
V1 (L/kg) 0.273 (0.026) 0.291 (0.035) 0.216 ± 0.330 
V2 (L/kg) 0.309 (0.032) 0.316 (0.048) 0.229 ± 0.388 
Q (L/h/kg) 0.199 (0.035) 0.186 (0.036) 0.139 ± 0.259 
CL_AGE 0.023 (0.001) 0.023 (0.003) 0.018 ± 0.028 
CL,V1,V2_ALB 0.049 (0.012) 0.049 (0.017) 0.021 ± 0.078 
BSV V2 0.079 (0.046) 0.079 FIX 0.079 FIX 
BOV CL 0.083 (0.026) 0.080 (0.037) 0.023 ± 0.144 
Residual variability 0.044 (0.012) 0.043 (0.014) 0.021 ± 0.066 
Abbreviations: SE (standard error, expressed as variance); CL, clearance; V1, volume of the central compartment; V2, volume of the peripheral 483 
compartment; BSV, between-subject variability; BOV, between occasion variabili484 
 Table 3.Cumulative fraction of predicted response to achieve targets of 40%, 60% and 80% T>MIC for 10meropenem dosage 
regimens against strains of E.coli, coagulase negative Staphylococcus, E. faecalis and P. aeruginosa. 
   Cumulative Fraction of Predicted Response (%) 
 
  E. coli 
coagulase negative 
Staphylococcus 
E.faecalis P.aeruginosa 
 Dose / 
interval Clearance 
40% 
T>MIC 
60% 
T>MIC 
80% 
T>MIC 
40% 
T>MIC 
60% 
T>MIC 
80% 
T>MIC 
40% 
T>MIC 
60% 
T>MIC 
80% 
T>MIC 
40% 
T>MIC 
60% 
T>MIC 
80% 
T>MIC 
O
v
e
r 
5
 m
in
u
te
s
 
1g/ 
8h 
CL <10 L/h 100 100 100 100 100 99 93 89 84 95 93 92 
10<CL<20 L/h 100 100 100 99 99 99 74 60 47 88 84 81 
CL>20 L/h 100 100 100 99 98 98 50 28 18 83 77 72 
2 g/ 
8h  
CL <10 L/h 100 100 100 100 100 100 98 96 93 99 97 96 
10<CL<20 L/h 100 100 100 100 99 99 92 84 72 94 91 88 
CL>20 L/h 100 100 100 99 99 99 79 58 42 89 84 80 
1 g/ 
6h 
CL <10 L/h 100 100 100 100 100 100 96 93 90 98 96 94 
10<CL<20 L/h 100 100 100 99 99 99 88 72 64 91 87 86 
CL>20 L/h 100 100 100 99 99 98 70 48 32 87 82 77 
1 g/ 
4 h 
CL <10 L/h 100 100 100 100 100 100 98 97 97 99 99 98 
10<CL<20 L/h 100 100 100 100 100 99 93 91 85 95 94 91 
CL>20 L/h 100 100 100 99 99 99 85 77 70 91 89 85 
O
v
e
r 
3
 h
o
u
rs
 
1 g/ 
8 h 
CL <10 L/h 100 100 100 100 100 99 95 92 88 96 95 93 
10<CL<20 L/h 100 100 100 99 99 99 88 73 57 91 88 84 
CL>20 L/h 100 100 100 99 99 98 71 52 30 87 83 78 
2 g/ 
8 h 
 
CL <10 L/h 100 100 100 100 100 100 98 97 96 99 98 97 
10<CL<20 L/h 100 100 100 100 100 99 96 92 83 98 94 90 
CL>20 L/h 100 100 100 100 99 99 91 78 69 93 89 85 
1 g/ 
6 h 
CL <10 L/h 100 100 100 100 100 100 97 96 95 98 97 97 
10<CL<20 L/h 100 100 100 100 99 98 92 87 80 94 91 89 
CL>20 L/h 100 100 100 99 99 99 86 74 70 91 87 86 
O
v
e
r 
2
4
 h
o
u
rs
 
3 g/ 
24 h 
CL <10 L/h 100 100 100 100 100 100 95 95 94 97 97 96 
10<CL<20 L/h 100 100 100 100 100 100 89 89 89 92 92 92 
CL>20 L/h 100 100 100 99 99 99 76 75 74 88 88 87 
4 g/ 
24 h 
CL <10 L/h 100 100 100 100 100 100 97 97 97 99 99 98 
10<CL<20 L/h 100 100 100 100 100 100 94 90 89 96 92 92 
CL>20 L/h 100 100 100 99 99 99 86 83 81 91 90 89 
6 g/ 
24 h 
CL <10 L/h 100 100 100 100 100 100 99 99 98 99 99 99 
10<CL<20 L/h 100 100 100 100 100 100 97 96 94 98 96 95 
CL>20 L/h 100 100 100 99 99 99 92 89 88 94 91 91 
  
  
 
Figure 1: Serum concentration-time profiles of meropenem from 12 patients (20 occasions) with 
burn injury. Key: open circles 1 g every 8 h, open triangles, 1 g every 6 h, closed triangles 1 g 
every 4 h, closed squares 2 g every 8 h 
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 Figure 2.Prediction-corrected visual predictive check of the final model describing the PK of 
meropenem in patients with severe burn injuries. The solid lines represent the 5th, 50th and 
95th percentiles of the plasma meropenem concentrations and the model-based predictions of 
the percentiles and their 95% confidence intervals. 
 
  
Figure 3.Percentage probabilities of achieving a target 40% (left), 60% (middle) and 80% (right) T>MIC using 6 different meropenem 
dosage regimens. Key: open circles 1 g every 8 h over 5 min, closed circles 1 g every 8 h over 3 h, open squares 2 g every 8 h over 
5 min, closed squares 2 g every 8 h over 3 h, open triangles 3 g over 24 h, closed triangles 6 g over 24 h. 
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